Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q1 EPS of ($1.36), $0.11 worse than the analyst estimate of ($1.25). Revenue for the quarter came in at $62 thousand versus the consensus estimate of $210 thousand.

“Work is underway across the company as we prepare for the potential approval and launch of ripretinib later this year,” said Steve Hoerter, President and Chief Executive Officer of Deciphera. “We continue to make progress against our planned 2020 company milestones, including advancing our broad clinical-stage pipeline and completing enrollment in the ongoing, pivotal Phase 3 INTRIGUE study of ripretinib in second-line GIST.”

Mr. Hoerter continued, “In these unprecedented times, we remain steadfast in our mission to bring important new medicines to patients for the treatment of cancer. Our employees have done a tremendous job adapting to the COVID-19 related challenges we are facing as a company, and as an industry, to carry out this mission. We are continuing to actively evaluate the potential impact of the pandemic on our business and proactively explore and implement mitigation measures.”

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.